Abstracts

ENDING THE HIV EPIDEMIC: A PLAN FOR THE UNITED STATES

This presentation will describe the newly announced U.S. Department of Health and Human Services initiative targeting the ongoing HIV epidemic in the United States with the goals of decreasing the number of HIV incident infections by 75% within 5 years, and then by 90% within 10 years. This coordinated, multi-agency initiative will focus on geographic…

MISSING U: HANDLING AND AVOIDING MISSING DATA IN CLINICAL TRIALS

Randomized clinical trials are the gold standard for evaluation of interventions. However, the presence of missing data can compromise their benefits, and lead to bias and inappropriate study conclusions. While methods exist to handle missing data in analysis, these may appear intimidating to the statistician and non-statistician alike, and are generally under-utilized. Even when used,…

DESIGNING & INTERPRETING HIV PREVENTION TRIALS IN THE ERA OF EFFECTIVE INTERVENTIONS

Until recently, the design and analysis of clinical trials to evaluate HIV prevention interventions was relatively straightforward. Participants would be randomised to receive the intervention of interest or to receive no intervention (placebo under the most robust design). The analysis would compare HIV incidence rates between the groups, yielding an estimate of the effectiveness –…

INTERACTIVE CASE-BASED WORKSHOP ON LIVER DISEASE

This interactive case-based session is geared toward clinicians who are involved in treatment of HIV-infected patients with various liver diseases. Despite major recent breakthroughs in the treatment of viral hepatitis, there are important remaining challenges in the clinical care of those with liver diseases. This workshop will address difficult to treat HCV-coinfected patients who have…

DISCOVERY AND DEVELOPMENT OF HIV BROADLY NEUTRALIZING ANTIBODIES

Combination antiretroviral therapy (ART) has revolutionized the treatment and prevention of HIV-1 infection. Taken daily, ART prevents and suppresses the infection. However, ART interruption almost invariably leads to rebound viremia in infected individuals due to a long-lived latent reservoir of integrated proviruses. Therefore, ART must be administered on a life-long basis. The lecture will focus…

UPDATE ON HIV IMMUNOLOGY

Dr Moore will describe advances in eliciting protective antibodies by vaccination, highlight emerging insights at the interface between innate and adaptive immunity, and summarize key new immunological findings at CROI. Please see the session overview for the Program Committee Workshop for New Investigators and Trainees for a description of the session.